NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...
Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...
However, while some patients experience significant tremor relief with dopamine replacement therapies like L-DOPA, others see little to no improvement, or even a worsening of symptoms. “Tremor is a ...
In a public advisory, Health Canada says various ingredients were found in the unauthorized health products, including acetaminophen, DHEA (dehydroepiandrosterone), levodopa (aka L-dopa ...